Keytruda is a brand name for pembrolizumab, which is a type of immunotherapy drug that is used to treat cancer. The drug is manufactured by Merck & Co., Inc. [3]. Keytruda is a biologic drug that was approved by the FDA in 2014 for the treatment of advanced melanoma [2]. Since then, it has been approved for the treatment of several other types of cancer, including lung cancer, head and neck cancer, and bladder cancer [2]. In 2018, the FDA approved Keytruda in combination with chemotherapy for the treatment of metastatic cervical cancer [1]. Merck & Co., Inc. is a global pharmaceutical company that develops and manufactures a wide range of drugs, including vaccines, prescription medications, and animal health products [3]. Keytruda is one of the company's most successful drugs, generating billions of dollars in revenue each year [3].

Sources:
[1] https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-as-treatment-for-patients-with-persistent-recurrent-or-metastatic-cervical-cancer-whose-tum/
[2] https://www.keytruda.com/
[3] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA